Aerie Acquires Envisia Technology for $25M to Advance Retinal Program

October 6, 2017: By Jon Swedien

AerieAerie Pharmaceuticals announced Oct. 5 that it has acquired from Envisia Therapeutics the rights to use its PRINT technology in ophthalmology, along with certain other assets.

The PRINT technology is Envisia’s proprietary system for sustained-release products.

Under the terms of the agreement, Envisia will receive $25 million upfront in a combination of cash and Aerie common stock. Envisia, of Durham, North Carolina, could earn more based on certain product approval milestones, Aerie said.

Aerie, of Irvine, California, said it intends to use the technology to accelerate the advancement of its pipeline to treat conditions in the back of the eye, such as wet age-related macular degeneration and diabetic retinopathy.

Aerie’s initial focus will be in using PRINT to manufacture injectable implants containing its preclinical product candidate known as AR-13154, a potential wet AMD treatment.

This potentially could be done in conjunction with a biodegradable polymer from DSM, a Netherlands-based company that Aerie struck a collaborative agreement with in July.

In addition, Aerie acquired the intellectual property rights relating to ENV1105, Envisia’s preclinical dexamethasone steroid product candidate for the treatment of diabetic macular edema, which also uses the PRINT technology, Aerie said.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

US Health Secretary Alex Azar Takes Aim at Rebates in US Senate Hearing

Beyeonics Surgical Raises $11.5 Million in Initial Funding Round

MeiraGTx Raises $75 Million in Initial Public Offering

GenSight to Pursue Approval for LHON Gene Therapy Candidate, Despite Phase III Setback

Optovue Receives FDA Clearance for AngioAnalytics, First OCT Angiography Metrics

Nexy Robotic Retinal Imaging System Receives FDA Clearance

Ocutrx Receives US Patent for Oculenz AR Glasses for Macular Degeneration

Allergan’s Bimatoprost SR Demonstrates Noninferiority to Timolol in Phase III Glaucoma Study

KKR to acquire Envision Healthcare, Including Amsurg ASC Business

Ophthalmologist Carmen Puliafito, MD, Seeks to Regain Medical License

Avedro Gains J Code for Photrexa Formulations in Preliminary CMS Decision

EyeGate Seeks to Study Ocular Bandage Gel in Punctate Epitheliopathy

Nicox, Ironwood to Collaborate on Novel Ophthalmic Treatments

US FDA Approves MDGH’s Moxidectin for Treatment of River Blindness

Bausch + Lomb Enrolls First Patient in Trial for enVista MX60EF Trifocal IOL

Cincinnati Eye Institute Partners with Private Equity Firm to Pursue National Expansion

Ophthotech Enters Gene Therapy Deals with University of Florida, University of Pennsylvania

Teva’s Launches Generic Version of Restasis in Canada

Clearside’s Phase II Trial for DME Candidate Meets Primary Endpoint

Orasis Raises $13 Million in Series B Financing

Coming soon

2018 Optical Coherence Tomography Report: A Global Market Analysis for 2017 to 2023